Key facts
- This page summarizes Mark Gustafson's Form 4 filing for Alzamend Neuro, Inc. (ALZN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Mar 2022, 19:12.
Mark Gustafson - 15 Mar 2022 Form 4 Insider Report for Alzamend Neuro, Inc. (ALZN)
- Reporting relationship
- Director
- Issuer ticker
- ALZN
- Reported as of
- 15 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Mar 2022, 19:12:26 UTC
- Prior SEC filing
- 16 Dec 2021
- Next SEC filing
- 04 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Gustafson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Gustafson filed Form 4 for Alzamend Neuro, Inc. (ALZN) on 15 Mar 2022.
Change
- Previous filing in this sequence was filed on 16 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALZN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +50,000
- Change %
- +167%
- Price
- $0.000000
- Shares after
- 80,000
- Date
- 15 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALZN
transaction
Derivative
Restricted Stock Grant
Options Exercise
- Transaction value
- $0
- Shares
- -50,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents the vesting of restricted stock.
Footnote F2
Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc.
Footnote F3
2,778 and 47,222 restricted shares previously vested on September 13, 2021 and October 13, 2021, respectively, with the final 50,000 shares of restricted stock vesting on March 15, 2022.